Evaluation of Bevacizumab combined with chemotherapy for the first-line treatment on patients with metastatic Colorectal Cancer
GAO Wen
LIU Lingxiang
ZHU Weiyou
XU Jing
SHU Yongqian
Abstract：Objective To evaluate the efficacy and safety of Bevacizumab plus chemotherapy for the first-line treatment on patients with metastatic Colorectal Cancer(mCRC).Methods Previously untreated 30 pa-tients with mCRC received treatment of L-OHP based on chemotherapy (FOLFOX or CapeOx)(n =18)or CPT-11 based on chemotherapy (FOLFIRI)(n =12)plus Bevacizumab.Bevacizumab was given with 5mg /kg every 2 weeks,or 7.5 mg/kg every 3 weeks.Response of treatment was evaluated during the treatment,and tox-icity was recorded at the same time.The survival time of these patients was also observed.The data were retro-spectively analyzed.Results 15 of 30 patients had partial responses and 10 patients got stable status and 5 pa-tients got progressive disease.The response rate was 50% and control rate of the disease was 83.3%.The me-dian progression free survival(PFS)was 10.809 months(95%CI:4.079 ~15.921).The adverse events related to Bevacizumab were hypertension on 3 patients,epistaxis on 1 patient,proteinuria on 1 patient.2 patients suf-fered from myelosuppression,and 4 patients suffered tardive diarrhea.Conclusion Bevacizumab combined with chemotherapy treatment is effective and the adverse effect is well to tolerated,which could be used as the first-line treatment for patients with mCRC.
Keywords：metastatic colorectal cancerbevacizumabfirst-line chemotherapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 345-349 )